Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche - LARVOL DELTA

Ulcerative Necrobiosis Lipoidica in the Setting of Oropharyngeal Epstein-Barr Virus Positive Diffuse LargCell Lymphoma and Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report (AAD 2026) - "Anti-inflammatory topical clobetasol 0.05% ointment was initiated as well as a saline based solution containing hypochlorous acid for wound cleansing. Due to secondary infection, the patient’s topical regimen was modified to include gentamicin 0.1% ointment and mupirocin 2% ointment followed by eventual broad-spectrum IV antibiotics. Notably, dapsone was avoided due to known G6PD as well as other immunosuppressants in the setting of DLBCL and ongoing chemotherapy with rituximab, cyclophosphamide, doxorubicin, (vincristine), and prednisone (R-CHOP) which had induced neutropenia and thrombocytopenia...Additionally, pegfilgrastim and platelet infusions for neutropenia and thrombocytopenia were administered after initiating R-CHOP. The noninfectious granulomatous reactions may have been an early sign of the underlying lymphoma, suggesting DLBCL as a contributing factor to NL disease pathogenesis."

Case report • Clinical • B Cell Lymphoma • Diabetes • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Immunodeficiency • Thrombocytopenia

Single Center Experience: Bendamustine Associated Neutropenia with or without Pegfilgrastim (HOPA 2026) - "In progress"

Clinical • Chemotherapy-Induced Neutropenia • Febrile Neutropenia • Hepatology • Liver Failure • Neutropenia

Measuring the Move: Quantitative Insights into Stem Cell Mobilization (HOPA 2026) - "Reviewing and updating stem cell mobilization protocols can improve efficiency of collection while reducing institutional costs associated with chair time. This retrospective review demonstrated that the addition of "rescue" G-CSF to pegfilgrastim and plerixafor in patients with low CD34 counts was a successful strategy, with 100% of the patients collecting adequate amount of stem cells to proceed to transplant and 96% meeting the collection goal."

Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • CD34 • CXCR4

GCSF Utilization Post UCM Procedural Changes: Evaluation of Product Availability and Clinical Outcomes from Any Delay in Care (HOPA 2026) - "Prior to July 2024, patients at the University of Chicago Medicine (UCM) receiving inpatient chemotherapy requiring GCSF support were eligible to be discharged to an outpatient infusion center to receive Neulasta Onpro, an on-body injection formulation of pegfilgrastim, within 24 hours after hospital discharge. Results pending"

Clinical • Clinical data • Febrile Neutropenia • Hematological Disorders • Neutropenia

Incidence of Febrile Neutropenia in Early-Stage Breast Cancer Patients Receiving Same Day Versus Next Day Pegfilgrastim for Primary Prophylaxis (HOPA 2026) - "Currently in the data collection phase with results shared at the HOPA conference."

Clinical • Breast Cancer • Febrile Neutropenia • Neutropenia • Oncology • Solid Tumor

Real-World evidence of eflapegrastim (efla) usage in patients with gastrointestinal (GI) malignancies (AACR 2026) - "Background: Long-acting granulocyte colony-stimulating factors (GCSFs) such as efla and pegfilgrastim (peg) are routinely used to prevent neutropenia in patients (pts) with cancer undergoing neutropenia-inducing chemotherapy...Chemotherapy regimens included FOLFIRI (35% vs 21%) and FOLFOX (48% vs 34%)... Pts receiving chemotherapy for GI malignancies who were treated with efla were older and had a higher burden of comorbidities than those treated with peg. The incidence of FN was similar and low between treatments. Other AEs were also comparable between the two groups."

Clinical • HEOR • Real-world • Real-world evidence • Anal Carcinoma • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

IMPACT OF CD34⁺ CELL DOSE AND GROWTH FACTOR SUPPORT ON EARLY MORBIDITY AND NON-RELAPSE MORTALITY AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR LYMPHOMA (EBMT 2026) - "33% of patients received plerixafor and/or an additional cycle of cytarabine or cyclophosphamide to mobilise progenitor cells. We did not demonstrate a significant association between CD34+ dose in ASCT and 180-day NRM. CD34+ doses <4×10⁶/kg were associated with a higher rate of ICU admission and a composite adverse outcome. We found similar clinical outcomes with pegfilgrastim compared with filgrastim."

CNS Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Transplantation

IMPACT OF CD34⁺ CELL DOSE AND GROWTH FACTOR SUPPORT ON EARLY MORBIDITY AND NON-RELAPSE MORTALITY AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR LYMPHOMA (EBMT 2026) - "33% of patients received plerixafor and/or an additional cycle of cytarabine or cyclophosphamide to mobilise progenitor cells. We did not demonstrate a significant association between CD34+ dose in ASCT and 180-day NRM. CD34+ doses <4×10⁶/kg were associated with a higher rate of ICU admission and a composite adverse outcome. We found similar clinical outcomes with pegfilgrastim compared with filgrastim."

CNS Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Transplantation

Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial. (PubMed, Ann Intern Med) - P=N/A | "Administration of pegfilgrastim 72 hours postchemotherapy reduced PIBP compared with 24- and 48-hour administration and did not seem to be associated with higher rates of neutropenia or FN. National Natural Science Foundation of China."

Journal • P3 data • Breast Cancer • Febrile Neutropenia • Hematological Disorders • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor

Summary for Patients: Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain. (PubMed, Ann Intern Med) - No abstract available

Journal • Musculoskeletal Pain • Pain

Claudin- 6 (CLDN6) is a therapeutic target in ovarian cancer (OC): Emerging results from the CATALINA 1 (CAT1) study (ESMO 2025) - P1 | "For all OC: median prior lines 3 (1-9); 73% received prior bevacizumab, 67% prior PARP inhibitors, and 11% prior mirvetuximab. OC pts received doses 3.0 mg/kg (11) with doses ≥3.0 mg/kg given with prophylactic pegfilgrastim (peg)...TORL-1-23 was generally well tolerated with an acceptable safety profile. These proof-of-concept data support further evaluation of TORL-1-23 in larger, registration studies that are now ongoing."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CLDN6

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=38 | Not yet recruiting | Sponsor: Michael Spinner, MD | Trial completion date: Apr 2033 ➔ Oct 2033 | Initiation date: Oct 2025 ➔ May 2026 | Trial primary completion date: Oct 2028 ➔ Mar 2029

Circulating tumor DNA • Trial completion date • Trial initiation date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Phase 1 Study. of Docetaxel/Cisplatin/Cemiplimab (TPI) Induction Chemoimmunotherapy (ICI) in Untreated Locally Advanced Head and Neck Squamous Cancer. (MHNCS 2026) - P1 | "Subjects received Neulasta on day 4 of chemotherapy cycle. TPI multidisciplinary treatment in patients with LAHNC was effective and feasible. There were minimal acute immune related toxicities. A toxicity of laryngeal edema and necrosis in the post CRT period was seen in 3 larynx patients treated with 7000 cGy and not in the subsequent 2 patients treated with 6000 cGy suggesting a significant dose related and site specific IT/CRT interaction."

Metastases • P1 data • Gastroenterology • Gastrointestinal Disorder • Head and Neck Cancer • Immunology • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma

Cancer-associated thrombosis presenting as multiple brain infarctions during complete remission of follicular lymphoma. (PubMed, Intern Med) - "After the fourth cycle of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and pegfilgrastim, the patient presented with dysarthria and right upper-limb paresis...Anticoagulation with unfractionated heparin, followed by apixaban, resulted in neurological improvements. The patient was discharged without bleeding or any neurological sequelae. This case highlights that CAT can occur even in indolent lymphoma during CR and that anticoagulation is effective and safe despite the presence of thrombocytopenia."

Journal • Brain Cancer • Cardiovascular • CNS Disorders • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Oncology • Thrombocytopenia • Thrombosis

CA244-0010: IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy (clinicaltrialsregister.eu) - P2/3 | N=193 | Not yet recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

New P2/3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

D7402C00001: A trial to learn how safe AZD0486 is and how well it works in older or physically weak adults with large B-cell lymphoma when given after R-mini-CHOP (clinicaltrialsregister.eu) - P2/3 | N=30 | Not yet recruiting | Sponsor: AstraZeneca AB

New P2/3 trial • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CA2440012: Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy (clinicaltrialsregister.eu) - P2/3 | N=198 | Recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

New P2/3 trial • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

A UNIQUE PATTERN OF AVERAGE SALES PRICE EROSION OF PEGFILGRASTIM FOLLOWING BIOSIMILAR ENTRY INTO THE US MARKET (ISPOR 2026) - "Biosimilars entered markets with ASPs higher than pegfilgrastim ASPs. Reference pegfilgrastim ASPs showed an unusual pattern of decline relative to literature-reported ASP patterns for other reference biological agents post-biosimilar market entry; reflecting a unique defensive strategy by the manufacturer of reference pegfilgrastim. Findings also confirmed the general trend of decreases in ASP, highlighting biosimilars' role in lowering treatment costs and enhancing patient access."

Association Between Recent G-CSF Exposure and dd-cfDNA Levels After Heart Transplantation (ISHLT 2026) - "Purpose Granulocyte colony-stimulating factors (G-CSF), including filgrastim and pegfilgrastim, are commonly prescribed to orthotopic heart transplant (OHT) recipients for neutropenia...Effect sizes were negligible (Cohen's d: -0.28 to -0.19).Conclusion G-CSF exposure within 180 days before AlloSure testing was not associated with altered dd-cfDNA levels regardless of rejection status. Prospective studies with paired sampling during active treatment are needed to assess acute effects."

Cell-free DNA • Hematological Disorders • Infectious Disease • Neutropenia • Transplantation

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov) - P2 | N=33 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • ABL1 • CD20

GCSF-PAIN: G-CSF-Induced Bone Pain and Supportive Care Approaches (clinicaltrials.gov) - P=N/A | N=225 | Completed | Sponsor: Ankara Etlik City Hospital | Recruiting ➔ Completed | N=128 ➔ 225

Enrollment change • Trial completion • Chemotherapy-Induced Neutropenia • Hematological Disorders • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor

EMEG-ECDD: Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (clinicaltrials.gov) - P=N/A | N=97 | Completed | Sponsor: Centre Georges Francois Leclerc | Recruiting ➔ Completed

Trial completion • Breast Cancer • Oncology • Solid Tumor

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) (ASH 2023) - "All Pts received pegfilgrastim and zoster prophylaxis. KR-CHOP can be delivered safely, without excess cardiac toxicity or peripheral neuropathy. The superior PFS and OS rates for Pts with non-GC DLBCL vs. controls receiving R-CHOP are encouraging but should be interpreted with caution due to inherent selection bias in clinical trial populations."

Clinical • P1/2 data • Anemia • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Heart Failure • Hematological Malignancies • Herpes Zoster • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Plasmacytoma • Pulmonary Disease • Thrombocytopenia

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Cytokine use in the Hematopoietic Subsyndrome of Acute Radiation Syndrome (H-ARS): Implications for the role of cytokines in a mass casualty radiologic/nuclear (R/N) emergency. (PubMed, J Radiol Prot) - "Ease of use favored pegfilgrastim (administered weekly x2) and romiplostim (administered once), compared to filgrastim and sargramostim (administered daily x5 and x14, respectively). Formal assessment of the published evidence is urgently needed to provide categorical guidance regarding cytokine use for patient management, and to public health officials involved in establishing a national or shared regional radiation stockpile for immediate use in a mass casualty radiological/nuclear (R/N) emergency."

Journal • Hematological Disorders • Oncology